Benefit of Nivolumab/Ipilimumab in MSI-H/dMMR Metastatic Colorectal Cancer Maintenance Beyond First Line
An analysis of the benefits of nivolumab/ipilimumab in MSI-H/dMMR metastatic colorectal cancer on progression free survival rate.
Read More
Author: Rebecca Shover
Equivalent Benefit of Video Delivered & in Person Delivered Palliative Care
Virtual or in person palliative care has shown significant results for patients with non-small cell lung cancer that is incurable.
Read More
Perioperative Chemotherapy Outperforms Neoadjuvant Chemoradiation in Resectable Oesophageal Cancer
Patients with resectable oesophageal cancer have better results with perioperative chemotherapy and surgery than neoadjuvant chemoradiation and surgery.
Read More
Metformin Does Not Prevent Progression of Low Risk Prostate Cancer
Metformin, has been found to not benefit patients with low risk prostate cancer.
Read More
Batiraxcept-Paclitaxel Combination Shows Promise in High AXL-Expressing, Platinum-Resistant Ovarian Cancer
Batiraxcept and paclitaxel as a combination therapy has shown significant results in improving progression free survival and overall rates.
Read More
Crohn’s & Colitis eBook
A curated ebook on Crohn’s and colitis featuring recent studies, findings, and opinions from thought leaders.
Read More
Highly Significant Event Free Survival Benefit With Neoadjuvant Ipilimumab/Nivolumab in Stage 3 Melanoma
Patients with macroscopic stage 3 melanoma have seen improvements with neoadjuvant ipilimumab/nivolumab intake.
Read More
No Survival Benefit of Tumor Debulking for Patients With Multiorgan Metastatic Colorectal Cancer
A phase 3 trial has found that there is no survival benefit for tumor debulking in addition to palliative combination chemotherapy.
Read More
Adding Abemaciclib to Fulvestrant Improves Progression-Free Survival in Advanced HR+/HER2-Negative Breast Cancer After Progression on CDK4/6 Inhibitor and Endocrine Therapy
Abemaciclib in combination with fulvestrant can benefit progression free survival rates in patients with HR+/HER2-negative breast cancer.
Read More
First-Line Lorlatinib Provides Unprecedented Improvement for Patients With Advanced ALK+ NSCLC
An analysis has found that lorlatinib did not reach median progression free survival rates.
Read More
IV Iron for Patients With HFrEF and Iron Deficiency: Efficacy, Outcomes, and Future Directions
Recent studies highlight the growing interest surrounding the use of IV iron for patients with HFrEF and iron deficiency.
Read More
Tardive Dyskinesia eBook
A curated ebook on tardive dyskinesia featuring recent studies, findings, and opinions from thought leaders.
Read More
Study Shows Disparities in Palliative Care Use for Patients With Hepatocellular Carcinoma
Researchers at the 2024 ASCO Annual Meeting found racial and ethnic disparities in palliative care use among patients with advanced hepatocellular carcinoma.
Read More
Fixed-Duration Regimen Substantially Benefits PFS in Patients With CLL/SLL
Fixed duration ibrutinib plus venetoclax benefited survival outcomes in patients with high-risk CLL/SLL over more than 5 years of follow-up.
Read More
Examining Mortality in Patients With Multiple Myeloma and the Role of Infectious Diseases
Investigators examined the changes in mortality rates due to COVID-19, influenza, and pneumonia in patients with MM.
Read More
Survival Outcomes in Early-Stage NSCLC With Rare Mutations
The treatment landscape for non-small cell lung cancer has significantly evolved with the advent of targeted therapies.
Read More
10 Predictions From the Beginning of 2024: Are They Still True?
In the Physician’s Weekly podcast‘s first episode of 2024, host Rachel Giles, MD, and PW editorial board member Alex McDonald, MD, discussed their perspectives on anticipated medical breakthroughs.
Read More
Medical Fiction: Memorial Day and a Flag Misfortune
Dr. Leesa Cornell, CMO, confronts Benjamin Huffman, insurance executive, at a Memorial Day picnic, where tensions rise over insurer policies and ED crowding.
Read More